National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 |
| Procedure | open |
| OCID | ocds-h6vhtk-02ab4a |
Awards (4)
This procurement was awarded to 4 suppliers. Values shown are per-award; the notice total is ·.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Baxter Healthcare Ltd shared | · | · | active |
| ITH Pharma shared | · | · | active |
| Qualasept Ltd t/a Bath ASU shared | · | · | active |
| Quantum Aseptic Services shared | · | · | active |
description
NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. Period of framework agreement: 1 April 2021 to 31 March 2022 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 28 Apr 2021 | Contract award notice (F03) | Earlier regulations | 009177-2021 |
more from The NHS Commissioning Board (operating under the name of NHS England)
- Implementation of GP referral pathway to NHS CPCS · £1,700,000 · 12 May 2022
- NHS England and NHS Improvement - Independent Clinical Reviews into Deaths in Custody – South East Health & Justice, Detained Estates · 29 Apr 2022
- Provision of Benchmarking Performance Against the Learning Disability Improvement Standards for NHS Trusts · £800,000 · 18 Mar 2022
- PMO Support for the Cancer Healthcare and AI in Health and Care Programmes · £2,000,000 · 3 Mar 2022
- NHS Framework for the North of England, Branded Medicine · £863,999,552 · 1 Mar 2022
- NHS Framework for Midlands and East, Branded Medicines – Tranche A and Annual · £216,078,796 · 22 Feb 2022
- NHS National Generic Pharmaceuticals Wave 13 · £1,637,875,080 · 14 Jan 2022
- Targeted Lung Health Check Programme: External Quality Assurance of Radiologists · £800,000 · 22 Dec 2021
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.